Non-physiological levels of circulating cortisol in growth hormone-treated hypopituitary adults after conventional cortisone substitution.
OBJECTIVE
To assess the usefulness of measuring plasma cortisol profiles in growth hormone-treated hypopituitary adults and to compare these with cortisol levels in healthy controls.


METHODS
Eleven ACTH-deficient adult patients received 12.5 mg cortisone-acetate orally at 16.00 h and 25 mg at 07.00 h. The patients arrived in the ward at 12.00 h. After tablet intake at 16.00 h, samples for serum cortisol were taken at hourly intervals for the next 24 h, except between 07.00 and 12.00 h when samples were drawn every half hour; 24-h urinary free cortisol (24-h-UFC) excretion was collected simultaneously. For comparison, 8 healthy controls were investigated.


RESULTS
The patients had circulating cortisol levels with very low plasma cortisol at 07.00 h before their morning dose of cortisone acetate. At the same time period, controls had their highest plasma cortisol levels. After tablet intake the patients had a rapid initial absorption of cortisol, but a marked variability in the morning peak levels (Cmax), and the Cmax was in general higher and occurred 90 min later than the Cmax in the controls. The 24-h-UFC excretion and 24-h area under the curve (24-h-AUC) did not differ between patients and controls. The female patients had higher 24-h-AUC for plasma cortisol (p=0.032) and tended to have higher plasma cortisol peaks in the morning, but had levels of 24-h-UFC similar to those of the male patients.


CONCLUSIONS
Conventional cortisone substitution with a twice-daily replacement regimen in hypopituitary adults results in abnormal circulating cortisol profiles with low or non-measurable morning values and variable individual peaks. This suggests that the present dosing schemes have to be improved and that cortisone substitution should be individualized.
Blomgren
J
J
Division of Internal Medicine, Department of Medicine and Care, University Hospital, Linköping, Sweden. Johan.Blomgren@ltjkpg.se
Ekman
B
B
Andersson
P O
PO
Arnqvist
H J
HJ
D000328:Adult; D000368:Aged; D001835:Body Weight; D003348:Cortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use* / Q000652:urine; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood* / Q000652:urine*; D007018:Hypopituitarism / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012727:Sex Characteristics; D013997:Time Factors
D013006:Growth Hormone; D003348:Cortisone; D006854:Hydrocortisone